Page 20 - Read Online

Page 14 of 20 Manrique et al. Microbiome Res Rep 2024;3:23 https://dx.doi.org/10.20517/mrr.2023.80

FUTURE PERSPECTIVES AND CONCLUSIONS
As we commented previously, the successful story of FMT as a treatment for C. difficile has opened the door
to research and regulation of microbiome-based therapies. With the approval of three therapies by the
pertinent regulatory bodies and the increasing number of clinical trials worldwide, it is evident that
microbiome-based therapies are here to stay. Nevertheless, significant efforts still need to be made to
completely understand the mechanisms of action by which these therapies exert their effect, as well as to
develop new formulations aimed at improving their scalability and reinforcing their safety. In addition, the
close relationship between gut microbiome and immune system modulation, altogether with the
development of new bioinformatic tools, such as AI, could lead to the blooming of new patient-tailored
solutions.

Microbiome research is a rapidly evolving field, demanding full recognition not only from the regulatory
agencies, but also from researchers and industrial partners. This collective acknowledgment is crucial for
devising optimal solutions to various health issues and technological challenges where the gut microbiota
could be implicated.

DECLARATIONS
Authors’ contributions
Conceived the idea: Martinez N, Cantabrana CH, Manrique P, Rios-Covian D
Wrote the manuscript: Manrique P, Montero I, Fernandez-Gosende M, Martinez N, Rios-Covian D
Designed the figures: Manrique P
Drafted and reviewed the manuscript: Manrique P, Rios-Covian D
All authors have revised and approved the final version of the manuscript.

Availability of data and materials
Not applicable.

Financial support and sponsorship
Montero I holds a Torres Quevedo postdoctoral grant (PTQ2020-01141) and Fernandez-Gosende M holds a
Doctorado Industrial grant (DIN2021-012075), both from the Spanish Ministry of Science and Innovation.

Conflicts of interest
All authors belong to Microviable Therapeutics, a company focused on the development of microbiome-
based therapeutics. However, no conflict of interest is present in this manuscript.

Ethical approval and consent for publication
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2024.

REFERENCES
1. Teusink B, Smid EJ. Modelling strategies for the industrial exploitation of lactic acid bacteria. Nat Rev Microbiol 2006;4:46-56. DOI
PubMed
2. Zannini E, Waters DM, Coffey A, Arendt EK. Production, properties, and industrial food application of lactic acid bacteria-derived